EndoPredict breast cancer testing

One Test - Three Clinical Answers for Breast Cancer Patients

EndoPredict is the ONLY predictive and prognostic test to answer three critical clinical questions…

Can
chemotherapy be avoided?

Risk at 10 years1

What is the absolute benefit from chemotherapy?

Chemotherapy benefit2

Can endocrine therapy be stopped after 5 years?

Risk up to 15 years3

… to optimize treatment for N0/N+ breast cancer patients of each age

Less
Chemotherapy
Optimal
Treatment
Long Term
Confidence
Less
Chemotherapy
Optimal
Treatment
Long Term
Confidence

EndoPredict is a gene expression assay

for patients with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) early stage breast cancer who are lymph node negative or positive (N0, N1, micrometastases).

This second generation test combines a 12-Gene Molecular Score with tumor size and nodal status to provide more prognostic power than any other test.

EndoPredict Provides Superior Prognostic Performance - Results You Can Trust

• Identifies the most women with breast cancer at true low risk in head-to-head comparison with competitors.
• Leads to a significant impact on therapy decision to give the right therapy to the right patient.
• Predicts individualized absolute chemotherapy benefit for confident treatment decisions.
• Provides 10 year and up to 15 year risk prediction for long term confidence.
• Offers definitive risk classification in low or high risk.
• Delivers fast result by local testing.

EndoPredict provides an individualized test result for each patient that allows for a quick, easy to understand risk assessment that can help deciding whether to safely forego chemotherapy or extended endocrine therapy.

Filipits M. et al.: A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors. Clin Cancer Res. 2011; 17(18):6012-6020
Sestak I. et al.: Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast Cancer Res Treat. 2019; 176:377-386
Filipits M. et al.: Prediction of Distant Recurrence using EndoPredict among Women with ER+, HER2- Node- Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only. Clin Cancer Res. 2019;25:3865-3872
Buus et al. Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy. J Natl Cancer Inst. 2016 Jul 10; 108(11)
Sestak I. et al.: Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer. A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018; 4(4):545-553
Muller B.M. et al.: The EndoPredict Gene-Expression Assay in Clinical Practice – Performance and Impact on Clinical Decisions. PloSONE. 2013; 8(6): e68252
Penault-Llorca et al.: A prospective multicenter non-randomized trial evaluating the effect of EndoPredict® (EPclin®) clinicogenomic test on treatment decision making among patients with intermediate clinical risk. SABCS 2016
Ettl J. et al.: Decision Impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker UPA/PAI-1. PLoSONE. 2017; 12(9): e0183917

Physicians

I am a physician looking to find critical answers about my patients’ cancer to provide peace of mind.

Patients

I am a patient looking for answers that will help guide cancer treatment decisions and provide peace of mind.

Pathologists

I am searching for an EndoPredict provider or I am interested in running EndoPredict in my laboratory.

News from ASCO
Identifying Pre-Menopausal Patients Who Do Not Need Chemotherapy

Further Confirmation of the Use of EndoPredict in Young Patients

Recent data from ASCO 2021 reconfirm the reliable long-term prognosis by EndoPredict. In a study of 385 pre-menopausal patients with up to three affected lymph nodes, treated with adjuvant endocrine therapy alone and a median follow-up time of 9.7 years, EndoPredict successfully identified two-thirds of patients with low risk of distant recurrence that could safely forego chemotherapy.

  • 65% of patients were classified as EPclin low-risk
  • The EPclin low-risk group had a significantly lower rate of distant recurrence (3%) compared to the high-risk group (24%)
  • EPclin Risk Score was strongly associated with 10-year DRFS regardless of nodal status.

EndoPredict is validated for both post- and pre-menopausal patients. These data highlight the importance of testing pre-menopausal women with ER+, HER2- breast cancer with EndoPredict.

Please read the clinical summary here for further information

ASCO 2021 (Constantinidou A. et al., J Clin Oncol 39, 2021 (suppl 15; abstr 537)